A Study of the Effect of Concomitant Administration of BMS-708163 on the Pharmacokinetics of Donepezil in Healthy Subjects is a PHASE1 clinical asset sponsored by Bristol-Myers Squibb in Alzheimer Disease. SEO and diligence focus: Donepezil, BMS-708163, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.